4D Molecular Therapeutics (FDMT) Cash & Equivalents Growth (1y) (2020 - 2026)
4D Molecular Therapeutics (FDMT) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - | -45.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.71% |
| Dec 31, 2025 | -59.66% |
| Sep 30, 2025 | -74.11% |
| Jun 30, 2025 | -59.19% |
| Mar 31, 2025 | -51.55% |
| Dec 31, 2024 | -40.05% |
| Sep 30, 2024 | -31.97% |
| Jun 30, 2024 | -19.99% |
| Mar 31, 2024 | 250.77% |
| Dec 31, 2023 | 375.84% |
| Sep 30, 2023 | 154.56% |
| Jun 30, 2023 | 108.23% |
| Mar 31, 2023 | 3.42% |
| Dec 31, 2022 | -65.78% |
| Sep 30, 2022 | 19.02% |
| Jun 30, 2022 | -53.44% |
| Mar 31, 2022 | -70.77% |
| Dec 31, 2021 | -44.71% |
| Dec 31, 2020 | 457.33% |